肿瘤恶液质药物治疗进展

doi:10.16689/j.cnki.cn11-9349/r.2020.04.005

Abstract
Figure/Table
References (0)
Related Citation (4)

Download: PDF (455 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Cancer cachexia mainly contains the gradual decrease of muscle mass, anorexia, fatigue, and impaired functional status, which seriously affects the quality of life and survival time of patients. Among them, gastrointestinal and pulmonary malignancies are the most common. Drug therapy plays an important role in the comprehensive treatment, but currently the more commonly used drugs, such as appetite stimulants and some drugs to control symptoms, have unsatisfactory efficacy. In recent years, many metabolic regulators, targeted drugs and traditional Chinese medicine have shown good efficacy and tolerance in the treatment of cancer cachexia, such as ghrelin analogues, which promote growth and anabolic metabolism, and monoclonal antibodies which inhibit catabolic metabolism. The treatment of cachexy requires comprehensive intervention of clinical multidisciplinary collaboration, which can be controlled and even reversed. We made a comprehensive review on the progression of current drug therapy for cancer cachexia.

Key words： cancer cachexia Drug therapy Metabolic regulation Ghrelin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wang Lin

Cite this article:

Wang Lin. Research progress of drug therapy for cancer cachexia[J]. Electron J Metab Nutr Cancer, 2020, 7(4): 402-406.

URL:

http://182.92.200.144/EN/10.16689/j.cnki.cn11-9349/r.2020.04.005 OR http://182.92.200.144/EN/Y2020/V7/I4/402

1.AOYAGI T, TERRACINA K P, RAZA A, et al. Cancer cachexia, mechanism and treatment［J］. World J Gastrointest Oncol, 2015, 7(4):17-29.
2.KRZNARIC , JURETIC A, DOMISLOVIC V, et al. Ten years of Croatian national guidelines for use of eicosapentaenoic acid and megestrol acetate in cancer cachexia syndrome - Evaluation of awareness and implementation among Croatian oncologists［J］. Clin Nutr ESPEN, 2019, 33:202-206.
3.SHARMA R A, STEWARD W P, DAINES C A, et al. Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: Phase I clinical trial of three dosing schedules in patients with solid malignancies［J］. Eur J Cancer, 2006, 42(14):2318-2325.
4.RIECHELMANN R P, BURMAN D, TANNOCK I F, et al. Phase II trial of mirtazapine for cancer-related cachexia and anorexia［J］.Am J Hosp Palliat Care, 2010, 27(2): 106-110.
5.DEWEY A, BAUGHAN C, DEAN T, et al. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia［J］. Cochrane Database Syst Rev, 2007, 2007(1):CD004597.
6.MAZZOTTA P, JENEY C M. Anorexia-cachexia syndrome: A systematic review of the role of dietary polyunsaturated fatty acids in the management of symptoms, survival, and quality of life［J］. J Pain Symptom Manage, 2009, 37(6):1069-1077.
7.RIES A, TROTTENBERG P, ELSNER F. A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: An EPCRC cachexia guidelines project［J］. Palliat Med, 2012, 26(4): 294-304.
8.PAPPALARDO G, ALMEIDA A1, RAVASCO P. Eicosapentaenoic acid in cancer improves body composition and modulates metabolism［J］. Nutrition, 2015, 31(4):549-55.
9.李世伟, 马怀幸, 李苏宜. ω-3多不饱和脂肪酸治疗癌性恶病质系统评价及荟萃分析［J］. 肠外与肠内营养, 2017, 24(1):28-32.
10.SATOU M, NAKAMURA Y, ANDO H, et al. Understanding the functional significance of ghrelin processing and degradation［J］. Peptides, 2011, 32(11):2183-2190.
11.FUJITSUKA N, UEZONO Y.Rikkunshito, a ghrelin potentiator, ameliorates anorexia- cachexia syndrome［J］. Front Pharmacol, 2014, 10(5):271.
12.GARCIA J M, FRIEND J, ALLEN S. Therapeutic potential of anamorelin, a novel, orally available ghrelin mimetic, in patients with cancer-related cachexia: A multicenter, randomized, double-blind, crossover, pilot study［J］. Supportive Care in Cancer, 2013, 21 (1): 129-137.
13.TEMEL J S, ABERNETHY A P, CURROW D C, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials［J］. Lancet Oncol, 2016, 17(4):519-531.
14.CURROW D, TEMEL J S, ABERNETHY A, et al. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia［J］.Ann Oncol, 2017, 28(8):1949-1956.
15.KATAKAMI N, UCHINO J, YOKOYAMA T, et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)［J］. Cancer, 2018, 124(3):606-616.
16.HAMAUCHI S, FURUSE J, TAKANO T, et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia［J］. Cancer, 2019, 125(23):4294-4302.
17.FUJITSUKA N, ASAKAWA A, UEZONO Y, et al. Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival［J］. Transl Psychiatry, 2011, 1(7):e23-e33.
18.OHNISHI S, WATARI H, KANNO M, et al. Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02)［J］. J Gynecol Oncol, 2017, 28(5):e44.
19.SUN L L, LAI H Z, CHEN Z Z, et al. Modified Liujunzi decoction alleviates chemotherapy-induced anorexia in advanced non-small cell lung cancer: a propensity score matched case-control study［J］. Chin J Integr Med, 2020, 26(4):256-262.
20.CHEN J M, YANG T T, CHENG T S, et al. Modified Sijunzi decoction can alleviate cisplatin-induced toxicity and prolong the survival time of cachectic mice by recovering muscle atrophy［J］. J Ethnopharmacol, 2019, 233:47-55.
21.CHEN Y, CHEN H, SUN B. Chinese herbal medicine Sijunzi decoction alleviates liver cancer cachexia through downregulating TGF-β and IGF 1 signaling pathways［J］. Ann Oncol, 2019, 30(Supl.4):264.
22.ZHANG Y N, HAN X C, BING O Y, et al. Chinese herbal medicine baoyuan jiedu decoction inhibited muscle atrophy of cancer cachexia through antrogin-Ⅰ and MuRF-1［J］. Evid Based Complement Alternat Med, 2017, 2017:6268378.
23.ASP M L, TIAN M, WENDEL A A, et al. Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice［J］. Int J Cancer, 2009, 126(3):756-763.
24.PENNA F, BONETTOA, MUSCARITOLI M, et al. Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved［J］? Int J Cancer, 2010, 127(7):1706-1717.
25.HONG Y, LEE J H, JEONG K W, et al. Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy［J］. J Cachexia Sarcopenia Muscle, 2019, 10(4):903-918.
26.HONORS M A, KINZIG K P. Chronic exendin-4 treatment prevents the development of cancer cachexia symptoms in male rats bearing the Yoshida sarcoma［J］. Horm Cancer, 2014, 5(1):33-41.
27.SOLOMON Z J, MIRABAL J R, MAZUR D J, et al. Selective androgen receptor modulators: current knowledge and clinical applications［J］. Sex Med Rev, 2019, 7(1):84-94.
28.CRAWFORD J, PRADO C M, JOHNSTON M A, et al. Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (power trials)［J］. Curr Oncol Rep, 2016, 18(6):37.
29.SALAZAR-DEGRACIA A, BUSQUETS S, ARGILS J M, et al. Effects of the beta2 agonist formoterol on atrophy signaling, autophagy, and muscle phenotype in respiratory and limb muscles of rats with cancer-induced cachexia［J］. Biochimie, 2018, 149:79-91.
30.TOLEDO M, BUSQUETS S, PENNA F, et al. Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist［J］. Int J Cancer, 2016, 138(8):2021-2029.
31.MOLFINO A, AMABILE M I, ROSSI FANELLI F, et al. Novel therapeutic options for cachexia and sarcopenia［J］. Expert Opin Biol Ther, 2016, 16(10):1239-1244.
32.HATAKEYAMA S, SUMMERMATTER S, JOURDAIN M, et al. ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments［J］. Skelet Muscle, 2016, 6:26.
33.BAYLISS T J, SMITH J T, SCHUSTER M, et al. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer［J］. Expert Opin Biol Ther, 2011, 11(12):1663-1668.
34.PRADO B L, QIAN Y. Anti-cytokines in the treatment of cancer cachexia［J］. Ann Palliat Med, 2019, 8(1):67-79.
35.BERTI A, BOCCALATTE F, SABBADINI M G, et al. Assessment of tocilizumab in the treatment of cancer cachexia［J］. J Clin Oncol, 2013, 31(23):2970.
36.ANDO K, TAKAHASHI F, KATO M, et al. Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer［J］. PLoS One, 2014, 9(7):e102436.
37.MIYAMOTO Y, HANNA D L, ZHANG W, et al. Molecular pathways: Cachexia signaling-a targeted approach to cancer treatment［J］. Clin Cancer Res, 2016, 22(16):3999-4004.
38.OSULLIVAN COYNE G, BUROTTO M. MABp1 for the treatment of colorectal cancer［J］. Expert Opin Biol Ther, 2017, 17(9):1155-1161.
39.HONG DS, HUI D, BRUERA E, et al. MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: An open-label, phase 1 dose-escalation and expansion study［J］. Lancet Oncol, 2014, 15(6):656-666.
40.FISHER GA. A phase Ⅲ study of xilonix in refractory colorectal cancer patients with weight loss［J］. J Clin Oncol, 2015, 33(suppl 3):685.
41.MCDONALD J J, MCMILLAN D C, LAIRD B J A. Targeting IL-1α in cancer cachexia: a narrative review［J］. Curr Opin Support Palliat Care, 2018, 12(4):453-459.
42.FINN R S, AHN D H, JAVLE M M, et al. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer［J］. Invest New Drugs, 2018, 36(6): 1037-1043.
43.QUAN-JUN Y, YAN H, YONG-LONG H, et al. Selumetinib attenuates skeletal muscle wasting in murine cachexia model through ERK inhibition and AKT activation［J］. Mol Cancer Ther, 2017, 16(2):334-343.
44.Au E D, Desai A P, Koniaris L G, et al. The MEK-inhibitor Selumetinib attenuates tumor growth and reduces IL-6 expression but does not protect against muscle wasting in Lewis lung cancer cachexia［J］. Front Physiol, 2017, 7:682.
45.PRADO C M, BEKAII-SAAB T, DOYLE L A, et al. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma［J］. Br J Cancer, 2012, 106(10):1583-1586.
46.JATOI A, DAKHIL S R, NGUYEN P L, et al. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group［J］. Cancer, 2007, 110(6):1396-1403.
47.JATOI A, RITTER H L, DUECK A, et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance nonsmall cell lung cancer patients (N01C9)［J］. Lung Cancer, 2010, 68(2):234-9. 67.
48.WIEDENMANN B, MALFERTHEINER P, FRIESS H, et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia［J］. J Support Oncol, 2008, 6(1):18-25.